Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document References Conclusions Appendix References EntrestoⓇ (slide 7 references) 1 IQVIA National Prescription Audit. 2 Approved indications differ by geography. Examples include "indicated to reduce the risk of cardiovascular death and hospitalization for HF in adult patients with CHF. Benefits are most clearly evident in patients with LVEF below normal." (US), HFrEF (EU), HFrEF and HTN (China) and CHF and HTN (JP). HTN is not an approved indication in the US and EU. 3 AHA/ACC/HFSA/ESC. 4 Extension of regulatory data protection to November 2026 in EU based on approval of pediatric indication. Company overview Financial review KesimptaⓇ (slide 9 references) 1 Data on file. Global data as of Nov 2023. 2 Data on file. 3 Kappos et al., AAN 2020, Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials. 4 5 As per stability technical specification data, when the patient is ready to inject, it typically takes less than 1 minute a month to administer. Once-monthly dosing begins after the initial dosing period, which consists of 20 mg subcutaneous doses at weeks 0, 1, and 2. Patient must take pen out of the refrigerator 15-30 minutes before self-administering.. Please see Instructions for Use for more detailed instructions on preparation and administration of KESIMPTA. Ross AP, Nicholas J, Tai MH, et al. US Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis. LB09. Presented at: Consortium of Multiple Sclerosis Centers Annual Meeting; May 31-June 3, 2023; Aurora, CO. 6 Novartis KESIMPTA Sensoready® Pen survey HEORUSV201392 in US. June 2022. 7 Efficacy outcomes as measured by disability progression and brain volume change. 8 Cohen et al, Poster presented at American Academy of Neurology, Boston, 22-27 April 23. 9 Cohen et al, oral presentation at American Academy of Neurology, Boston, 22-27 April 23. □ NOVARTIS Reimagining Medicine Novartis Q4 Results | January 31, 2024 86

View entire presentation